Efficacy of 23-valent Pneumococcal Polysaccharide Vaccine in Steroid Responsive Nephrotic Syndrome

Hahn, Hye-Won; Ha, Il-Soo; Cheong, Hae-Il; Lee, Hoan-Jong; Choi, Yong

J Korean Soc Pediatr Nephrol > Volume 6(1); 2002 > Article

J Korean Soc Pediatr Nephrol 2002;6(1): 56-60.

스테로이드 반응성 신증후군 환아에서 23-valent pneumococcal polysaccharide vaccine의 예방효과

한혜원, 하일수, 정해일, 이환종, 최용

¹서울대학교 의과대학 소아과학교실
²서울대학교 의과대학 소아과학교실
³서울대학교 의과대학 소아과학교실
⁴서울대학교 의과대학 소아과학교실
⁵서울대학교 의과대학 소아과학교실

Efficacy of 23-valent Pneumococcal Polysaccharide Vaccine in Steroid Responsive Nephrotic Syndrome

Hye-Won Hahn, Il-Soo Ha, Hae-Il Cheong, Hoan-Jong Lee, Yong Choi

¹Department of Pediatrics, Seoul National University College of Medicine
²Department of Pediatrics, Seoul National University College of Medicine
³Department of Pediatrics, Seoul National University College of Medicine
⁴Department of Pediatrics, Seoul National University College of Medicine
⁵Department of Pediatrics, Seoul National University College of Medicine

ABSTRACT

Purpose Streptococcus pneumoniae is a major pathogen in both adults and children, causing significant morbidity and mortality In patients with nephrotic syndrome, Streptococcus pneumoniae is a major cause of spontaneous peritonitis, and the increasing incidence of penicillin-resistance strain facilitates the development of effective vaccine. The limitation of current pneumococcal polysaccharide vaccine prompted development of polysaccharide- protein conjugate vaccine.
Methods: We reviewed the medical record of total 225 steroid responsive nephrotic patients to ascertain the effectiveness of 23- valent pneumococcal polysaccharide vaccine. Results. Twenty- eight patients have developed peritonitis during the courses, and 7 of those have recurrent peritonitis. Fifty- five patients were vaccinated and followed- up for 1- 108 months (mean 38.5 months), and during the follow- up period, pneumococcus related peritonitis was not detected. Vaccine- related relapse of nephrotic syndrome w as absent.
Conclusion : In spite of the non- consensus about the efficacy of PPV23, clinically it benefits, and until the clinical trial of PCV7 is completed, PPV23 will be recommended. (J Korean Soc Pediatr Nephrol 2002;6: 56-60)

Key words: Nephrotic syndrome | Peritonitis | S. pneumoniae | Pneumococcal vaccine